Bio-Rad has purchased Quantalife and is now offering its digital PCR (Polymerase Chain Reaction) system, which is designed to provide quantification of target molecules with precision and sensitivity.
According to the company, this next-generation PCR technology builds on the well-established method of amplifying DNA that is used in research laboratories around the world.
Digital PCR provides researchers with a new tool for the detection of rare mutations, including distinguishing rare sequences in tumours, precise measurement of copy number variation and absolute quantification of gene expression.
